Application of adaptive study designs: Phase II and III results from the cediranib (CED) HORIZON (HZ) II and III studies.
D. Wilson, A Stone(Stone Age Institute), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), P. M. Hoff, Jane Robertson(Cancer Research UK)
Cited by 2
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
|The Lancet Oncology|2012|526
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
|Annals of Oncology|2016|344
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303